Targets › FNTA
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.
Essential subunit of both the farnesyltransferase and the geranylgeranyltransferase complex. Contributes to the transfer of a farnesyl or geranylgeranyl moiety from farnesyl or geranylgeranyl diphosphate to a cysteine at the fourth position from the C-terminus of several proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. May positively regulate neuromuscular junction development downstream of MUSK…. (UniProt, P49354)
Open in Phaseline: the race on FNTA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Tipifarnib Protein farnesyltransferase inhibitor | FNTA, FNTB | Phase 2 | Malignant Solid Neoplasm | Sep 2027 |
| Giselle Sholler | Tipifarnib Protein farnesyltransferase inhibitor | FNTA, FNTB | Phase 2 | Neuroblastoma | Dec 2030 |
| Kura Oncology | Darlifarnib Farnesyltransferase inhibitor | FNTA | Phase 1 | Solid Tumors With HRAS Alterations | Jan 2027 |
Malignant Solid Neoplasm (1) Solid Tumors With HRAS Alterations (1) Neuroblastoma (1)
small molecule (2), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.